A PHASE 1B/2, OPEN-LABEL STUDY OF Q702 IN COMBINATION WITH INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS

Seung-Tae Kim, Hong Jae Cho, Do-Youn Oh, Jaspreet Grewal, Sun Young Rha, Anthony El-Khoueiny, Baek-Yiel Ryoo, Seongjun Kim, Hyunj Ahn*, Seung-Hee Ryu, Jinho Choi, Bae Jung Choi, Jije Ahn, Hwankyu Kang, Yeo-In Yang, Seung-jo Lee, Borami Jeon, Stefan Proniuk, Kye-an Nam, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; CHA Bundang Medical Center, CHA University, Seongnam-si, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Norton Cancer Institute, Louisville, KY, USA; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; Asian Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Qurient Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea

Background Q702 is a novel Axl/Mer/CSF1R inhibitor, able to modulate the tumor-associated macrophage (TAM) and myeloid-derived suppressor cell (MDSC) populations leading to CD8+ T cell activation and an increased antigen presentation of the tumor cells in syngeneic animal models. Q702 demonstrates additive effects with anti-PD-1 treatment, particularly in high myeloid containing tumor models through stimulation of innate immune components of the tumor microenvironment and elevated antigen presentation of cancer cells, which are considered the main obstacles for T cell activation by PD-1 or PD-L1 related immune checkpoint inhibitors. This data indicates that Q702 and pembrolizumab combination therapy may be a potential treatment option to enhance the activity of anti-PD-1/anti-PD-L1 treatment. The ongoing Q702 monotherapy phase 1 study (NCT04648254) has established 100 mg as a safe starting dose for the pembrolizumab combination study. The Part 2 Dose (P2D) for the combination therapy will be determined once the recommended phase 2 dose (RP2D) for Q702 monotherapy study is established.

Methods A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors (NCT05438420) is currently enrolling patients in the US and Korea. This study is to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in approximately 142 subjects with advanced esophageal, gastric/GEJ, hepatocellular and cervical cancers whose disease progressed within 12 weeks of last anti-PD-1 or PD-L1 related immune checkpoint inhibitors. This data indicates that Q702 and pembrolizumab combination therapy may be a potential treatment option to enhance the activity of anti-PD-1/anti-PD-L1 treatment. The ongoing Q702 monotherapy phase 1 study (NCT04648254) has established 100 mg as a safe starting dose for the pembrolizumab combination study. The Part 2 Dose (P2D) for the combination therapy will be determined once the recommended phase 2 dose (RP2D) for Q702 monotherapy study is established.

Trial Registration NCT05438420

REFERENCE